<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061580</url>
  </required_header>
  <id_info>
    <org_study_id>2009-1</org_study_id>
    <nct_id>NCT01061580</nct_id>
  </id_info>
  <brief_title>BMAC Enhanced Coronary Artery Bypass Grafting (CABG)</brief_title>
  <official_title>Dose Response Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting (CABG) Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvest Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harvest Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Injection of concentrated bone marrow cells into the myocardium during CABG procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Injection of autologous concentrated bone marrow cells into the myocardium during CABG&#xD;
      procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in left ventricular function</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QOL (Rand 36; Minnesota Living with Heart Failure Questionnaire)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA or CCS classification evaluation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular ejection fraction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular end-diastolic volume</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>CABG plus BMAC Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Harvest SmartPReP2 BMAC System</intervention_name>
    <description>Injection of 10, 15, or 20 cc of BMAC</description>
    <arm_group_label>CABG plus BMAC Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be enrolled in the trial:&#xD;
&#xD;
          -  Age 18 years and ability to understand the planned treatment.&#xD;
&#xD;
          -  Patients with ischemic congestive heart failure requiring by pass surgery&#xD;
&#xD;
          -  Congestive heart failure with ejection fraction 40%.&#xD;
&#xD;
          -  Serum bilirubin, SGOT and SGPT 2.5 time the upper level of normal.&#xD;
&#xD;
          -  Serum creatinine &lt; 3.0 or no dialysis.&#xD;
&#xD;
          -  NYHA performance status &gt; 3.&#xD;
&#xD;
          -  Negative pregnancy test (in women with childbearing potential).&#xD;
&#xD;
          -  Subject has read and signed the IRB approved Informed Consent form&#xD;
&#xD;
          -  Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000,&#xD;
             Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT&#xD;
             &lt;1.5 x control (to avoid bleeding complications) Patients on Coumadin will be&#xD;
             corrected prior to the procedure and must have an INR&lt;1.6 at the time of&#xD;
             randomization/surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded if they meet any of the exclusion criteria:&#xD;
&#xD;
          -  Female who is pregnant or nursing, or of child bearing potential and is not using a&#xD;
             reliable birth control method, or who intend to become pregnant during the tenure of&#xD;
             this study.&#xD;
&#xD;
          -  History of Prior Radiation Exposure for oncological treatment.&#xD;
&#xD;
          -  History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.&#xD;
&#xD;
          -  History of abnormal Bleeding or Clotting.&#xD;
&#xD;
          -  History of Liver Cirrhosis.&#xD;
&#xD;
          -  Acute Myocardial Infarction &lt; 4 weeks from treatment date.&#xD;
&#xD;
          -  Known active malignancy or results outside of normal limits from the following tests:&#xD;
             PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to&#xD;
             be cancer free.&#xD;
&#xD;
          -  Active clinical infection being treated by antibiotics within one week of enrollment&#xD;
&#xD;
          -  Terminal renal failure with existing dependence on dialysis&#xD;
&#xD;
          -  Inability or unwillingness to comply with the treatment protocol, follow-up, research&#xD;
             tests, or give consent.&#xD;
&#xD;
          -  Unable to have 250cc bone marrow harvested.&#xD;
&#xD;
          -  Medical risk that precludes anesthesia or ASA Class 5&#xD;
&#xD;
          -  History of ventricular arrhythmia if AICD is not present.&#xD;
&#xD;
          -  History of ventricular aneurysm.&#xD;
&#xD;
          -  Concurrent surgery such as CABG with valve surgery.&#xD;
&#xD;
          -  Minimally Invasive bypass surgery&#xD;
&#xD;
          -  Life expectancy &lt;6 months due to concomitant illnesses&#xD;
&#xD;
          -  Treatment with immunosuppressant drugs (including Prednisone &gt; 5 mg per day)&#xD;
&#xD;
          -  Patients undergoing urgent by pass surgical procedure&#xD;
&#xD;
          -  Patients with HGB A1C &gt; 8.5%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naresh Trehan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medanta-The Medicity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medanta The Medicity</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Marrow Concentrate</keyword>
  <keyword>CABG</keyword>
  <keyword>Cardiac</keyword>
  <keyword>Stem Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

